Truist Financial Issues Positive Forecast for BeOne Medicines (NASDAQ:ONC) Stock Price

BeOne Medicines (NASDAQ:ONC) had its price objective boosted by Truist Financial from $400.00 to $412.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently weighed in on ONC. Guggenheim increased their price target on shares of BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a research note on Friday. Citizens Jmp upped their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $405.00 price objective on shares of BeOne Medicines in a research note on Thursday, January 8th. Finally, Citigroup lifted their target price on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and a consensus price target of $394.25.

BeOne Medicines Stock Performance

Shares of NASDAQ ONC traded down $5.38 during trading hours on Friday, reaching $316.99. The stock had a trading volume of 364,170 shares, compared to its average volume of 252,166. The firm has a 50-day moving average of $336.81 and a 200-day moving average of $330.41. The firm has a market cap of $34.76 billion, a price-to-earnings ratio of 125.79 and a beta of 0.52. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. BeOne Medicines has a fifty-two week low of $196.45 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. Equities research analysts predict that BeOne Medicines will post -5.82 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Oyler sold 24,369 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total value of $7,380,639.03. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 102,656 shares of company stock valued at $31,567,496 in the last ninety days. Company insiders own 6.62% of the company’s stock.

Institutional Trading of BeOne Medicines

Several institutional investors have recently modified their holdings of the company. Capital International Investors raised its stake in shares of BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after acquiring an additional 67,808 shares during the last quarter. Primecap Management Co. CA acquired a new stake in BeOne Medicines during the 2nd quarter valued at $1,231,720,000. Temasek Holdings Private Ltd bought a new position in BeOne Medicines in the 2nd quarter valued at $244,603,000. Siren L.L.C. raised its position in BeOne Medicines by 1.4% in the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after purchasing an additional 7,010 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in BeOne Medicines in the second quarter worth $113,190,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.